What one share of Crispr Therapeutics Ag holds
Our mission is to create transformative gene-based medicines for serious human diseases. We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology.
Crispr Therapeutics Ag’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.14 |
|---|---|
| Profit | −$4.76 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$3.92 |
| Cash and investments | $24.46 |
| Debt | $6.06 |
| Book value | $18.07 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | — | −$5.06 | $0.23 | $11.57 | — | −$5.26 |
| 2016 | — | −$1.89 | $0.25 | −$4.56 | — | — |
| 2017 | — | −$1.71 | $0.20 | −$1.94 | — | $4.63 |
| 2018 | — | −$3.44 | $0.06 | −$2.06 | — | $7.56 |
| 2019 | — | $1.17 | $0.12 | $0.88 | — | $15.46 |
| 2020 | — | −$5.29 | $0.28 | −$3.89 | — | $22.52 |
| 2021 | — | $4.70 | $1.02 | $5.69 | — | $31.17 |
| 2022 | — | −$8.36 | $0.48 | −$6.85 | — | $23.89 |
| 2023 | $4.69 | −$1.94 | $0.12 | −$3.41 | — | $23.52 |
| 2024 | $0.44 | −$4.34 | $0.02 | −$1.72 | — | $22.53 |
| 2025 | $0.04 | −$6.47 | $0.01 | −$3.85 | — | $20.04 |
Common questions about Crispr Therapeutics Ag
How much does one share of Crispr Therapeutics Ag earn?
Over the last 12 months, Crispr Therapeutics Ag lost $4.76 for each share on $0.14 of sales.
Does Crispr Therapeutics Ag pay a dividend?
Crispr Therapeutics Ag didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Crispr Therapeutics Ag’s book value per share?
Crispr Therapeutics Ag’s book value is $18.07 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Crispr Therapeutics Ag have?
Each share of Crispr Therapeutics Ag has $24.46 of cash and investments and $6.06 of debt, as of June 30, 2026.
What is Crispr Therapeutics Ag’s free cash flow per share?
−$3.92 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Crispr Therapeutics Ag bought back shares?
Crispr Therapeutics Ag’s share count rose about 1685% from 2015 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.